The antischistosomal and antitrypanosomal
drug trans-5-amino-3-[2-(5-nitro-2-furyl)vinyl]-1,2,4-
oxadiazole [(
SQ18506) CAS: 28754-68-9; (E)-amino-3-(2-(5-nitro-2-furyl)-vinyl)-1,2,4-
oxadiazole] was carcinogenic for both male and female CD-1 mice when it was administered either in the diet or by gastric intubation. Dose-dependent increases in
tumors of the forestomach and lymphatic tissues were observed in all groups receiving
SQ18506 including mice infected with Schistosoma mansoni. The predominant
tumor observed was
squamous cell carcinoma of the forestomach. The presence or absence of schistosome
infection did not appear to alter the incidence or distribution of
tumors at comparable doses of
SQ18506. The incidence of
bladder tumors was positively correlated with the dose in gastric intubation studies and inversely correlated with the dose in dietary studies. The
carcinogen N-[4-(5-nitro-2-furyl)-2-thiazolyl]
formamide (CAS: 24554-26-5) was fed to male and female CD-1 mice in the diet as a positive control. The predominant
tumor observed in these groups was
transitional cell carcinoma of the bladder. These data indicate that
SQ18506 is unsuitable for use in the treatment of
parasitic diseases.